Ophthalmic gene therapy company Quethera was purchased by Astellas Pharma in a deal that gives Quethera upfront and contingent payments of up to $110.3 million. Quethera's lead program is an undisclosed gene therapy in preclinical testing for patients with glaucoma.
By using the CRISPR gene-editing tool to alter two of the more than 12 million nucleotides in the yeast genome, scientists from the University of Wisconsin-Madison and the Department of Energy were able to protect yeast from damage caused by pretreatment chemicals in biofuel production. The ionic liquids used in biofuel production can render yeast up to 70 percent less effective at converting sugar to biofuel.
Insulet CEO Patrick Sullivan says he plans to make Insulet a billion-dollar company focused on making lives of patients with type 1 diabetes easier. Growth plans center around its Omnipod tubeless insulin delivery technology, its new Dash configuration for wireless insulin management and its Horizon artificial pancreas system, expected to hit markets in late 2019 or early 2020.
Dexcom generated 42% higher year-over-year sales in the second quarter after the June launch of its G6 integrated continuous glucose monitoring system. The company is conducting validation and verification of the first-generation Verily miniature CGM device, in partnership with Verily, and is looking to release a second-generation version in 2021.
Israel-based Itamar Medical has filed a request with the Securities and Exchange Commission to be listed for trading on Nasdaq. The company, which makes home devices for sleep apnea diagnosis, is looking to secure regulatory approval for the next generation of its WatchPAT device by mid-2019.
An agreement has been reached by EKF Diagnostics with McKesson Medical-Surgical for the US distribution of the DiaSpect Tm reagent-free hemoglobin analyzer, a hand-held device that provides hemoglobin measurements using a broad-spectrum photometric method. The device will be offered by McKesson Medical-Surgical in the US as the McKesson Consult Hb analyzer, with a product launch scheduled this year.
A Research and Markets report predicts the worldwide interbody fusion cage market will hit $2.31 billion by 2023 with a 3.4% compound annual growth rate. Key market players include Medtronic, Zimmer Biomet, DePuy Synthes, NuVasive, B. Braun Melsungen and Orthofix International.
A Meddevicetracker report predicts the global liquid biopsy market will reach $2 billion by 2022 at a compound annual growth rate of 27.2%, driven by the increasing cancer incidence. Liquid biopsies are used most often for lung cancer, followed by breast, colorectal, stomach and prostate malignancies.
A pilot study of Medtronic's Extravascular Implantable cardioverter defibrillator system has begun, with the first implantation performed in New Zealand. The study will enroll 20 patients across four centers in Australia and New Zealand.